{
  "source": "PA-Notification-Piqray.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1290-7\nProgram Prior Authorization/Notification\nMedication Piqray® (alpelisib)\nP&T Approval Date 8/2019, 8/2020, 8/2021, 8/2022, 8/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nPiqray (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the\ntreatment of adults, with hormone receptor (HR)-positive, human epidermal growth factor\nreceptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following\nprogression on or after an endocrine-based regimen.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age\nof 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Piqray will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Breast Cancer\n1. Initial Authorization\na. Piqray will be approved based on all of the following criteria:\n(1) Diagnosis of breast cancer\n-AND-\n(2) One of the following:\n(a) Advanced\n(b) Metastatic\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(3) Disease is hormone receptor (HR)-positive\n-AND-\n(4) Disease is human epidermal growth factor receptor 2 (HER2)-negative\n-AND-\n(5) Presence of one or more PIK3CA mutations\n-AND-\n(6) Used in combination with fulvestrant\n-AND-\n(7) Disease has progressed on or after an endocrine-based regimen\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Piqray will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive dise",
    "docrine-based regimen\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Piqray will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Piqray therapy.\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\n1. The drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n© 2025 UnitedHealthcare Services, Inc.\n2\n4. References:\n1. Piqray [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. January 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed February 7, 2025.\nProgram Prior Authorization/Notification – Piqray (alpelisib)\nChange Control\n8/2019 New program.\n8/2020 Annual review. Updated formatting without change to clinical intent of\nprogram. Updated reference.\n8/2021 Annual review with no changes to coverage criteria. Updated references.\n8/2022 Annual review. Updated coverage criteria for initial authorization for\nbreast cancer to include premenopausal women treated with ovarian\nablation/suppression per NCCN Guidelines. Updated references.\n8/2023 Annual review with no changes to coverage criteria. Updated references.\n3/2024 Updated criteria reflecting new indicati",
    "ith ovarian\nablation/suppression per NCCN Guidelines. Updated references.\n8/2023 Annual review with no changes to coverage criteria. Updated references.\n3/2024 Updated criteria reflecting new indication for use is adults removing\ncriteria for postmenopausal, premenopausal with ovarian\nablation/suppression and male. Updated background and references.\n3/2025 Annual review with no changes to coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}